About the Program

Updated October 26, 2023

The Clinical Guidelines Program is a collaborative effort of the New York State Department of Health AIDS Institute (NYSDOH AI), Office of the Medical Director, and the Johns Hopkins University (JHU) School of Medicine, Division of Infectious Diseases. The Clinical Guidelines Program began in the late 1980s in response to the clinical management challenges of the HIV/AIDS epidemic in New York and has continuously provided clinical guidance for HIV care providers in New York State. As the NYSDOH AI has expanded its mission over time, so has this program, which now publishes timely, evidence-based clinical practice guidelines for HIV care and prevention and for treatment of viral hepatitis, other sexually transmitted infections (STIs), and substance use disorders (SUDs). Like the NSYDOH AI, the Clinical Guidelines Program also addresses healthcare and prevention for the LGBTQ+ community.

Mission: To produce and disseminate evidence-based, state-of-the-art clinical practice guidelines that establish uniform standards of care for practitioners who provide prevention or treatment of HIV, viral hepatitis, other STIs, and SUDs for adults throughout New York State in the wide array of settings in which those services are delivered.

Goals: As part of the NYSDOH AI Quality of Care Programs, the goal of the Clinical Guidelines Program is to support care providers in improving the health and well-being of adults in New York State who have or are at risk of acquiring HIV, viral hepatitis, other STIs, and SUDs. The Clinical Guidelines Program also supports the New York State Ending the Epidemic Initiative, including the HIV treatment-as-prevention strategy, with strong recommendations for increased testing and linkage to care, immediate initiation of antiretroviral therapy, increased awareness of acute HIV infection, and dedicated efforts to maintain HIV viral load suppression.

Expert committees: The NYSDOH AI Medical Director invites and appoints committees of clinical and public health experts from throughout New York State to ensure that the guidelines are practical, immediately applicable, and meet the needs of care providers and stakeholders in all major regions of New York State, all relevant clinical practice settings, key New York State agencies, and community service organizations.

Evidence-based recommendations: Committee members apply their expertise and experience in evaluating factors that determine treatment decisions, including potential benefits and outcomes, risks, and burdens to the patient; patient views, values, and preferences; feasibility and tolerability; and the quality of evidence supporting a treatment recommendation. All recommendations are assigned ratings based on the strength and quality of the supporting evidence.

Audience: NYSDOH AI clinical practice guidelines are produced and disseminated to clinicians in New York State. Guideline recommendations are based on published evidence and the collective expertise of committee members and are intended for use by specialists and low-volume care providers. The program is committed to publishing guidelines that are useful to busy care providers in their daily practice.

The NYSDOH AI has always sought to publish guidelines that inform primary care providers who do not specialize in HIV but do provide care for people with HIV within New York State. The guidelines are grounded in current research, supported by evidence, and reflect the breadth of experience of committee members who specialize in HIV, viral hepatitis, other STIs, and SUDs and who know the realities of providing clinical care throughout New York State and in a broad array of clinical settings.

Dissemination and implementation: All clinical practice guidelines are published and freely accessible on the Clinical Guidelines Program website. The NYSDOH AI disseminates the guidelines through multiple channels and numerous programs, and the Clinical Education Initiative provides training for care providers in New York State in support of guideline implementation.

Clinical Guidelines Program: The JHU School of Medicine, Division of Infectious Diseases, has collaborated with the NYSDOH AI since 1999 to develop and disseminate the AI clinical practice guidelines and related quality-of-care information. The Clinical Guidelines Program website is managed by JHU staff.

Funding: The Clinical Guidelines Program is supported by New York State funds allocated through a grant to the JHU School of Medicine to support all activities of the program.

Program Leadership and Staff

Updated October 26, 2023

New York State Department of Health AIDS Institute (NYSDOH AI): The Office of the Medical Director (OMD) oversees the program.

Charles J. Gonzalez, MD, Medical Director
Brianna L. Norton, DO, MPH, Deputy Medical Director
Lyn C. Stevens, MS, NP, ACRN, Clinical Advisor to the AIDS Institute
Laura Duggan Russell, MPH, AI Guidelines Program Director

The public health professionals of the NYSDOH AI OMD are dedicated to enhancing the quality of life for people with HIV by improving prevention and healthcare services. The OMD oversees numerous programs and initiatives including the following:

NYSDOH AI contact information: Laura Duggan Russell, Program Director: laura.russell@health.ny.gov. Office of the Medical Director, NYSDOH AIDS Institute, Empire State Plaza, Corning Tower, Room 259, Albany, NY 12237

Clinical Guidelines Program: Christopher J. Hoffmann, MD, MPH, MSc, Director, JHU-NYSDOH AI Clinical Guidelines Program, provides leadership and strategy, extensive experience in both HIV clinical care and guideline development, and a strong commitment to training for HIV care providers.

The JHU team manages all aspects of guideline development and dissemination and program administration through the efforts of the following program staff:

Mary Beth Hansen, MA, Program Director
Jennifer R. Ham, MPH, Senior Medical Editor
Johanna L. Gribble, MA, Senior Medical Editor
Rachel Lastra, Senior Medical Editor
Jesse M. Ciekot, Program Administrator

JHU contact information: Mary Beth Hansen, Program Director: mbh@jhmi.edu or Jesse Ciekot, Program Administrator: jciekot@jhmi.edu. General questions about the website can be emailed to: aiguidelines@jhmi.edu.

Guideline Development

Updated October 26, 2023

Expert committee composition: The Clinical Guidelines Program works directly with committees of experts in the field who represent multiple disciplines (medicine, nursing, psychology, pharmacy, public health, social work, mental health), clinical specialties (infectious diseases, family medicine, obstetrics and gynecology, hepatology, pediatrics, psychiatry, dentistry, prevention, etc.), and various geographic regions of New York State.

A Clinical Guidelines Program Steering Committee provides oversight and strategy to the following Clinical Guidelines Program committees, each of which is responsible for developing and updating clinical practice guidelines that fall under its area of expertise. Current committees (October 2023) include the following:

Financial disclosure and confidentiality agreement: All potential and active committee members are required to sign a confidentiality agreement and to disclose annually all financial relationships with commercial entities or gifts that may be actual, potential, or perceived as conflicts of interest. Committee members must report financial relationships with commercial entities that have existed in the 12 months before or are expected to exist in the 12 months after the date on which they sign their disclosure form.

Guideline development process: When the Clinical Guidelines Program identifies the need to develop or update a guideline, the committee under whose purview the guideline falls convenes to determine the goals and scope of the guideline, review the published literature, and weigh the evidence for recommendations. Text is then drafted by an author who has experience with the topic of the guideline. The guideline draft is edited by the JHU team and then reviewed and modified by the committee. This rigorous development process entails multiple rounds of review, revision, rating, committee approval, and editing. Decision-making occurs by consensus, and all guideline recommendations are reviewed by and receive the consensus approval of the full guideline committee.

Evidence-based recommendations: A letter rating is assigned to indicate the strength of each recommendation and a number rating is assigned to indicate the quality of the supporting evidence. Ratings are reached through review of the evidence and consensus decision. If the published evidence in support of a particular recommendation is insufficient, the group relies on collective experience and accepted best practices to develop a final statement. The rating scheme for recommendations appears below.

Recommendation Ratings Scheme
Strength		Quality of Evidence
Rating	Definition	Rating	Definition
A	Strong	1	Based on published results of at least 1 randomized clinical trial with clinical outcomes or validated laboratory endpoints.
B	Moderate	*	Based on either a self-evident conclusion; conclusive, published, in vitro data; or well-established practice that cannot be tested because ethics would preclude a clinical trial.
C	Optional	2	Based on published results of at least 1 well-designed, nonrandomized clinical trial or observational cohort study with long-term clinical outcomes.
		2†	Extrapolated from published results of well-designed studies (including nonrandomized clinical trials) conducted in populations other than those specifically addressed by a recommendation. The source(s) of the extrapolated evidence and the rationale for the extrapolation are provided in the guideline text. One example would be results of studies conducted predominantly in a subpopulation (e.g., one gender) that the committee determines to be generalizable to the population under consideration in the guideline.
		3	Based on committee expert opinion, with rationale provided in the guideline text.

External review: All guidelines are reviewed by external experts in the field and by the New York State Department of Health AIDS Institute (NYSDOH AI) Consumer Advisory Committee.

Final approval: The guideline is submitted to the NYSDOH AI Office of the Medical Director (OMD) for review and final approval before publication. The OMD may request additional review by other agencies and organizations when applicable.

Guideline updates: Members of guideline committees monitor developments in the field to ensure that guidelines remain up to date. Newly published data that provide support for existing recommendations will be cited in the text and reference list. If newly published data prompt a guideline revision, the committee’s writing group will propose appropriate edits and determine the need for full committee review and approval.

Medical Care Criteria Committee (MCCC; Adult HIV Treatment and Prevention)

Updated April 1, 2024
→ Committee members have no disclosures unless otherwise noted.

Writing Group

Chair: Rona M. Vail, MD, AAHIVS
Lead HIV Clinician, Callen-Lorde Community Health Center, New York, NY

Vice-Chair: Sanjiv S. Shah, MD, MPH, AAHIVM, AAHIVS
NYC Health + Hospitals/Gotham Health, Gouverneur, New York, NY

Chair Emeriti: Steven M. Fine, MD, PhD, Professor of Clinical Medicine, University of Rochester Medical Center, Rochester, NY; Joseph P. McGowan, MD, FACP, FIDSA, AAHIVS, Northwell Health, Manhasset, NY; Samuel T. Merrick, MD, FIDSA, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY

Transgender Health Specialist: Asa E. Radix, MD, MPH, PhD, FACP, AAHIVS
Callen-Lorde Community Health Center, New York, NY

Community Advisor: Jessica Rodrigues, MPH, MS
Senior HIV/Family Planning Advisor, USAID Office of HIV/AIDS, New York, NY

Deputy Medical Director: Brianna L. Norton, DO, MPH
New York State Department of Health AIDS Institute, New York, NY

Medical Director: Charles J. Gonzalez, MD
New York State Department of Health, AIDS Institute, New York, NY

Director, JHU-NYSDOH AI Guidelines Program: Christopher J. Hoffmann, MD, MPH, MSc, FACP
Johns Hopkins University School of Medicine, Division of Infectious Diseases, Baltimore, MD

Contributing Members

Elizabeth A. Asiago-Reddy, MD, MS
SUNY Upstate Medical University, Syracuse, NY

Jessica M. Atrio, MD, MSc
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

James C. M. Brust, MD
Professor of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

Michelle S. Cespedes, MD, MS
Icahn School of Medicine at Mount Sinai, New York, NY
Scientific advisor: Gilead Sciences, ViiV Healthcare

Ethan A. Cowan, MD, MS
Icahn School of Medicine at Mount Sinai, New York, NY

Mary E. Dyer, MD
Sun River Health, Poughkeepsie, NY

John J. Faragon, PharmD, BCPS, AAHIVP
Albany Medical Center, Albany, NY
Speakers bureau: Gilead Sciences; honorarium recipient: ViiV Healthcare

Shauna H. Gunaratne, MD, MPH, DTM&H
Columbia University Irving Medical Center, New York, NY

Bruce E. Hirsch, MD, FACP, FIDSA, AAHIVS
Northwell Health, Manhasset, NY

Christine A. Kerr, MD
Galileo Health

Jeremy D. Kidd, MD, MPH
Columbia University/New York State Psychiatric Institute, New York, NY

Hector I. Ojeda-Martinez, MD
Nuvance Health/Health Quest Medical Practice, Poughkeepsie, NY

Meera Shah, MD, MPH, MS, AAHIVS
Planned Parenthood Hudson Peconic, Elmsford, NY

Eugenia L. Siegler, MD, FACP
Weill Cornell Medical College, New York, NY

Maria Teresa (Tess) Timoney, MS, RN, CNM
Bronx Prevention Center, ICAP at Columbia, Bronx, NY

Benjamin W. Tsoi, MD, MPH
Director of HIV Prevention, Bureau of HIV/AIDS Prevention and Control, New York City Department of Health and Mental Hygiene, Long Island City, NY

Marguerite A. Urban, MD
University of Rochester School of Medicine and Dentistry, Rochester, NY

Antonio E. Urbina, MD
Professor of Medicine, The Mount Sinai Hospital, Comprehensive Health Program-Downtown, New York, NY
Scientific advisor: Gilead Sciences, Janssen, Merck, ViiV Healthcare

Geoffrey A. Weinberg, MD
University of Rochester School of Medicine and Dentistry, Rochester, NY

Changes to MCCC Membership

April 2024: Appointed Chair: Rona M. Vail, MD, AAHIVS, Lead HIV Clinician, Callen-Lorde Community Health Center, New York, NY. Appointed Vice-Chair: Sanjiv S. Shah, MD, MPH, AAHIVM, AAHIVS, NYC Health + Hospitals/Gotham Health, Gouverneur, New York, NY (formerly a contributing member). Appointed Chair Emeritus: Steven M. Fine, MD, PhD, Professor of Clinical Medicine, University of Rochester Medical Center, Rochester, NY

March 2024: Appointed to the writing group: Brianna Norton, DO, MPH, NYSDOH AI Deputy Medical Director (formerly a contributing member)

October 2023: Global update: Disclosures of financial relationships with commercial entities

June 2022: New contributing members: Elizabeth A. Asiago-Reddy, MD, MS, SUNY Upstate Medical University, Syracuse, NY; Michelle S. Cespedes, MD, MS, Icahn School of Medicine at Mount Sinai, New York, NY

April 2022: Appointed Chair: Steven M. Fine, MD, PhD, University of Rochester Medical Center, Rochester, NY. Appointed Chair Emeritus: Joseph P. McGowan, MD, FACP, FIDSA, North Shore University Hospital, Manhasset, NY

January 2022: New contributing member: Meera Shah, MD, MPH, MS, AAHIVS, Planned Parenthood Hudson Peconic. Stepped down: Oni J. Blackstock, MD, MHS, Health Justice

August 2021: Stepped down: Elliot DeHaan, MD, New York-Presbyterian Hospital/Weill Cornell Medical Center; Noga Shalev, MD, Columbia University Medical Center

July 2021: New writing group member: Jessica Rodrigues, AVAC

March 2021: New contributing members: John J. Faragon, PHARMD, BCPS, AAHIVP, Albany Medical Center; Shauna H. Gunaratne, MD, MPH, Columbia University Medical Center; Bruce E. Hirsch, MD, FACP, FIDSA, AAHIVS, North Shore University Hospital. Stepped down: John M. Conry, PharmD, AAHIVP, FNAP, St. John’s University; Annette Gaudino, Treatment Action Group (TAG); Jeremiah Johnson, Treatment Action Group (TAG); Eugene D. Morse, PharmD, FCCP, BCPS, University at Buffalo School of Pharmacy & Pharmaceutical Sciences

February 2021: New contributing member: Benjamin W. Tsoi, MD, MPH, Bureau of HIV/AIDS Prevention and Control, New York City Department of Health and Mental Hygiene

July 2020: New contributing member: Ethan A. Cowan, MD, MS, Icahn School of Medicine at Mount Sinai. Stepped down: Daniel J. Egan, MD, Columbia University Vagelos College of Physicians and Surgeons

January 2020: New contributing members: Jessica M. Atrio, MD, MSc, Albert Einstein College of Medicine/Montefiore Medical Center; Oni J. Blackstock, MD, MHS, New York City Department of Health and Mental Hygiene. Stepped down: Julie E. Myers, MD, MPH, New York City Department of Health and Mental Hygiene

December 2019: Stepped down: Jack Fuhrer, MD, Stony Brook University School of Medicine; Luz Amarilis Lugo, MD, Mount Sinai Comprehensive Health Program-Downtown; Cynthia H. Miller, MD, Albany Medical Center; David C. Perlman, MD, Icahn School of Medicine at Mount Sinai

Hepatitis C Virus (HCV) Guideline Committee

Updated October 26, 2023
→ Committee members have no disclosures unless otherwise noted.

Writing Group

Chair: Joshua S. Aron, MD
Elmhurst Hospital Center, Elmhurst, NY

Chair Emerita: Christine A. Kerr, MD
Galileo Health

Contributor: David E. Bernstein, MD, MACG, FAASLD, AGAF, FACP
NYU Langone Health, New York, NY

Medical Director: Charles J. Gonzalez, MD
New York State Department of Health AIDS Institute, New York, NY

Deputy Medical Director: Brianna L. Norton, DO, MPH
New York State Department of Health AIDS Institute, New York, NY

AIDS Institute Clinical Representative, Viral Hepatitis: Colleen Flanigan, RN, MS
Bureau of Hepatitis Health Care and Epidemiology, NYSDOH AI, Albany, NY

Director, JHU-NYSDOH AI Guidelines Program: Christopher J. Hoffmann, MD, MPH, MSc
Johns Hopkins University School of Medicine, Division of Infectious Diseases, Baltimore, MD

Contributing Members

Mary Angerame, MS, APN-BC
Jordan Health, Rochester, NY

Ayse Aytaman, MD, AGAF, FACG
Veterans Affairs New York Harbor Healthcare System, Brooklyn, NY

Donald P. Kotler, MD
Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY

Kristen Marks, MD
Weill Cornell Medical College, New York, NY

Andrew H. Talal, MD, MPH
SUNY Buffalo, Buffalo, NY

Jeffrey J. Weiss, PhD, MS
Mount Sinai School of Medicine, New York, NY

Changes to the HCV Guideline Committee

October 2023: Appointed to the writing group: Brianna Norton, DO, MPH, NYSDOH AI Deputy Medical Director (formerly a contributing member). Global update: Disclosures of financial relationships with commercial entities

April 2021: New contributing member: Andrew H. Talal, MD, MPH, SUNY Buffalo

March 2021: New contributing member: Donald P. Kotler, MD, Albert Einstein College of Medicine/Jacobi Medical Center. Stepped down: Annette Gaudino, Treatment Action Group (TAG)

September 2020: Stepped down: Ponni V. Perumalswami, MD, Icahn School of Medicine at Mount Sinai

February 2020: Appointed Vice-Chair: Ponni V. Perumalswami, MD, Icahn School of Medicine at Mount Sinai. Appointed Chair Emerita: Christine A. Kerr, MD, Galileo Health

Substance Use Guidelines Committee

Updated October 26, 2023
→ Committee members have no disclosures unless otherwise noted.

Writing Group

Chair: Susan D. Whitley, MD
SUNY Downstate Health Sciences University, Brooklyn, NY

Vice-Chair: Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM
Director of Addiction Medicine, Associate Professor of Emergency Medicine, University of Rochester Medical Center, Rochester, NY

Medical Director: Charles J. Gonzalez, MD
New York State Department of Health AIDS Institute, New York, NY

Deputy Medical Director: Brianna L. Norton, DO, MPH
New York State Department of Health AIDS Institute, Albany, NY

AIDS Institute Clinical Representative, Harm Reduction in Healthcare: Sharon L. Stancliff, MD
New York State Department of Health AIDS Institute, New York, NY

Director, JHU-NYSDOH AI Guidelines Program: Christopher J. Hoffmann, MD, MPH, MSc
Johns Hopkins University School of Medicine, Division of Infectious Diseases, Baltimore, MD

Contributing Members

Angela G. Giovanniello, PharmD, AAHIVP
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

Judith L. Griffin, MD
Cayuga Medical Center Internal Medicine Residency Program, Ithaca, NY

Julia K. Hunter, MD, MPH, FASAM
United Health Services Hospitals, Inc., Binghamton, NY

Giliane Joseph, MD
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

Tiffany Y. Lu, MD, MS, FASAM
NYC Health + Hospitals / Jacobi Medical Center, Bronx, NY

Yonina Mar, MBBS, MSc
Mount Sinai Beth Israel, New York, NY

Shadi Nahvi, MD, MS
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

David C. Perlman, MD
Icahn School of Medicine at Mount Sinai, New York, NY

Sara Lorenz Taki, MD
Greenwich House MMTP, New York, NY

Linda Wang, MD
Icahn School of Medicine at Mount Sinai, New York, NY

Changes to the Substance Use Guidelines Committee

June 2023: New contributing member: Linda Wang, MD, Icahn School of Medicine at Mount Sinai

October 2021: Appointed Chair: Susan D. Whitley, MD, New York City Health + Hospitals/Kings County. Appointed Vice-Chair: Timothy J. Wiegand, MD, University of Rochester Medical Center

August 2021: New contributing members: Judith L. Griffin, MD, REACH Medical; Julia K. Hunter, MD, MPH, FASAM, United Health Services Hospitals, Inc.; Tiffany Y. Lu, MD, MS, Albert Einstein College of Medicine/Montefiore Medical Center; Yonina Mar, MBBS, MSc, Mount Sinai Beth Israel; Sara Lorenz Taki, MD, Greenwich House MMTP

June 2021: Stepped down: Hillary Kunins, MD, MPH, MS, New York City Department of Health and Mental Hygiene

April 2021: Stepped down: Chinazo O. Cunningham, MD, MS, Albert Einstein College of Medicine/Montefiore Medical Center

March 2021: Stepped down: Annette Gaudino, Treatment Action Group (TAG); Raymond Harvey, MD, Institute for Family Health

July 2020: Stepped down: Marcus Bachhuber, MD, MS, Albert Einstein College of Medicine/Montefiore Medical Center; Michael L. Christie, MD, University of Rochester Medical Center; Kelly S. Ramsey, MD, MPH, MA, FACP, New York State Office of Addiction Services and Support

Institutional, Agency, and Program Liaison Advisory Group

Updated September 2023
→ Group members have no disclosures unless otherwise noted.

Sheldon T. Brown, MD
Infectious Diseases, Hudson Valley VA Healthcare System, Montrose, NY

Douglas Fish, MD
Office of Health Insurance Programs, New York State Department of Health, Albany, NY

Emma Kaplan-Lewis, MD
HIV Services, Office of Population Health, NYC Health and Hospitals, New York, NY

Ralph Liporace, MD
Coxsackie Correctional Facility, NYS Department of Corrections and Community Service, Albany NY

Kelly S. Ramsey, MD, MPH, MA, FACP, DFASAM
Independent Consultant in Addiction Medicine and Harm Reduction, Olivebridge, NY

William M. Valenti, MD, FIDSA
Senior Vice President for Strategic Advancement, Chief of Innovation, Staff Physician, Trillium Health, Rochester, NY; Medical Society of the State of New York

Changes to the Institutional, Agency, and Program Liaison Advisory Group

September 2023: Stepped down: Monica Parker, PhD, Bloodborne Viruses Laboratory, Wadsworth Center, NYSDOH

About This Website

Updated October 26, 2023

Purpose: This website publishes the clinical practice guidelines and related materials produced by the Clinical Guidelines Program, which is a collaborative effort of the New York State Department of Health AIDS Institute (NYSDOH AI) Office of the Medical Director (OMD) and the Johns Hopkins University School of Medicine, Division of Infectious Diseases (JHU). This website is produced, maintained, and managed by the Clinical Guidelines Program.

Terms of use: Although every possible effort is made to post accurate and reliable information on this website, neither the Clinical Guidelines Program, nor JHU, nor the NYSDOH AI assumes responsibility for the use or application of information posted on any page of this website or guarantees or warrants that the information posted on any page of this website is complete and without any error or inaccuracy. The website, its editors, advisers, staff, authors, and sponsoring institutions assume no responsibility for any error, omissions, or other discrepancies between the electronic documents published on this website and source materials. Physicians and other healthcare providers are encouraged to consult other sources and confirm the information contained in this website because no single reference or service can take the place of medical training, education, and experience. Healthcare consumers are cautioned that this website is not intended to provide medical advice regarding any specific medical condition or treatment and are encouraged to call or see their physician or other healthcare provider promptly with any health-related questions or concerns they may have.

This website links to websites maintained by other entities. Reasonable precautions are taken to link only to websites that publish appropriate and accurate material and are maintained by reputable organizations. However, those web pages are not under the direction or control of this website, and this website can therefore not be held responsible for the information or opinions expressed in those linked websites.

Editorial policies: The Clinical Guidelines Program does not provide medical advice or care. The materials published within this website do not purport to advance any official positions of JHU. Unless otherwise noted, all materials posted on this website have been produced under the auspices of the Clinical Guidelines Program. The Clinical Guidelines Program maintains editorial control of all materials published on this website. Mention of specific products by generic or brand name does not constitute an endorsement by the Clinical Guidelines Program, by its committee members, editors, or staff, or by the NYSDOH AI or its staff. Any mention of specific products is for informational purposes only. Regarding specific products or drugs, physicians and other healthcare providers are advised to consult their normal resources before prescribing to their patients.

Production and development:

Mary Beth Hansen, Managing Editor
Johanna L. Gribble, Website Manager
Alexei Yukna and Patrick Harris, WordPress development and programming
Laura Hatcher/Hatcher Design Office, Website design
Cyberian Frontier, Website hosting

Privacy: This website is designed to provide public access to the clinical practice guidelines published by the Clinical Guidelines Program. The program recognizes the importance of protecting the privacy of visitors to this website and of subscribers to the monthly Topic, Trends, and Updates email update.

Stored information: Most information transmitted over the Internet is not secure; thus, confidentiality cannot be guaranteed. However, of the information transmitted via your visit to the Clinical Guidelines Program website, we store the following: the IP address from which you access the Internet, the date and time, the Internet address of the website from which you linked directly to our website, the name of the file or the words you searched, and the browser used to access our website. This information is used to measure the number of visitors to the various sections of our website and identify system performance or problem areas. We also use this information to help us improve the features of the website and to make the website more useful.
Personally provided information: If you choose to provide us with personal information by sending an email or by subscribing to our monthly update and submitting that information through our website, we will use that information to respond to your message, to send you email that you have asked to receive, and to help us provide you with information or material that you may request. We do not give, share, sell, or transfer any of your personal information to a third party unless required by law. If you submit a question that would be best answered by a staff member of the NYSDOH AI, we may forward your question to that staff member. When we do, we may or may not include your email address so the staff member may respond to you directly. Submitting a question through this website constitutes your tacit agreement with the actions the JHU website managers may take to secure the best answer possible in a timely manner.
Links to other websites: For the convenience of those who access and use the content published on this website (i.e., the website users), many pages contain links to webpages and websites that are not managed by the Clinical Guidelines Program. Neither the Clinical Guidelines Program, nor JHU, nor the NYSDOH AI controls or takes responsibility for the content of those websites. Links from this website to websites not managed by any of the entities named above do not imply endorsement or credibility of the service, information, or product offered through the linked websites. Links are provided to make it easy for users to access supplementary content. Some pages on this website provide links to other websites that provide health information. Once a user links to another website, they are subject to the privacy policy of that other website.
Disclaimer: The information provided in this privacy statement should not be construed as giving business, legal, or other advice, or warranting as fail-proof, the security of information provided through this website.

Copyright and permissions: Copyright © Johns Hopkins University Clinical Guidelines Program 2000-2023. The Clinical Guidelines Program, a collaborative effort of the NYSDOH AI and the Johns Hopkins University School of Medicine, Division of Infectious Diseases, encourages the use, reproduction, and distribution of original documents and related graphics from this program website accompanied by a full citation of source that includes: Author(s). Committee. Title. Date of publication. Full URL. Date accessed. Links to pages on this Clinical Guidelines Program website are also encouraged and may be created without seeking permission. Requests to adapt material, i.e., to change or alter in any way material from this website for inclusion in another publication, should be sent to aiguidelines@jhmi.edu. Please include detailed information about the intended use and desired adaptations.

The names of the NYSDOH AI, JHU, Clinical Guidelines Program, or their staff may not be used in publicity or advertising without express written permission. Exceptions to this include listings on web indexes, search engines, and related systems.

Contact Us

Mailing address: JHU Clinical Guidelines Program, 600 North Wolfe Street, Carnegie 3, Rm 386, Baltimore, MD, 21287

E-mail addresses: General or content-specific comments or questions: aiguidelines@jhmi.edu; Program Director: mbh@jhmi.edu; Program Administrator: jciekot@jhmi.edu.

Note: The Clinical Guidelines Program is not a clinical consultative service. Individuals should consult with a care provider regarding specific patient needs and circumstances. Questions about individual and specific health issues cannot be answered.

Join our Mailing List

Stay up-to-date with the monthly Topics, Trends & Updates e-mail: The monthly Topics, Trends & Updates email keeps subscribers up-to-date regarding new and updated clinical guidelines, hot topics, upcoming events, developments in the field, and What We’re Reading.

Privacy: We do not sell, rent, or share our email lists with anyone.

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact